The FCF Healthcare & Life Sciences Venture Capital Monitor – Europe is a monthly overview of financing trends in the venture capital sector, with a focus on European healthcare and life sciences companies.
Total Healthcare & Life Sciences funding reached EUR 7,236m (+4% vs. 2025)
Biotech/Pharma received 33% of the total investment volume (EUR 2,397m), with oncology being the leading indication (35%)
In July, Neko Health (Sweden) secured the highest transaction volume with EUR 612m, followed by Draig Therapeutics (United Kingdom) with EUR 76m and Xeltis (Netherlands) with EUR 71m
GV (United States) is the most active investor (by deal volume in 2026), followed by Alphabet (United States) and CapitalG (United States)